COVID-19: A probable role of the anticoagulant Protein S in managing COVID-19-associated coagulopathy

Document Type

Article

Publication Date

8-19-2020

Publication Title

Aging

Abstract

The COVID-19 pandemic has caused monumental mortality, and there are still no adequate therapies. Most severely ill COVID-19 patients manifest a hyperactivated immune response, instigated by interleukin 6 (IL6) that triggers a so called "cytokine storm" and coagulopathy. Hypoxia is also associated with COVID-19. So far overlooked is the fact that both IL6 and hypoxia depress the abundance of a key anticoagulant, Protein S. We speculate that the IL6-driven cytokine explosion plus hypoxemia causes a severe drop in Protein S level that exacerbates the thrombotic risk in COVID-19 patients. Here we highlight a mechanism by which the IL6-hypoxia curse causes a deadly hypercoagulable state in COVID-19 patients, and we suggest a path to therapy.

First Page

15954

Last Page

15961

PubMed ID

32826388

Volume

12

Issue

16

This document is currently not available here.

Share

COinS